Contemporary treatment of systemic lupus erythematosus: an update for clinicians

Amissah-Arthur, Maame-Boatemaa; Gordon, Caroline

doi:10.1177/2040622310380100

Cited by 63 publications

(56 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk for NVD was much higher in SLE patients than in controls and several factors could contribute to this higher risk, including medications to control disease activity or prevent flares, such as antimalarials. These treatments have been reported to have gastrointestinal side effects such as nausea and vomiting . Although antimalarial use was higher in patients with NVD, as other studies have reported in patients with rheumatic diseases, this possible association was not found in the multivariable analysis.…”

Section: Discussionmentioning

confidence: 59%

“…These treatments have been reported to have gastrointestinal side effects such as nausea and vomiting. 20 Although antimalarial use was higher in patients with NVD, as other studies have reported in patients with rheumatic diseases, 21 this possible association was not found in the multivariable analysis. Notably, the controls included in this study also had a high prevalence of FGIDs (54.1%), which was similar to that reported in the Mexican population (58.4%).…”

Section: Discussionmentioning

confidence: 73%

See 1 more Smart Citation

Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study

Garcı́a-Carrasco

Mendoza‐Pinto

Munguía‐Realpozo

et al. 2019

Neurogastroenterology Motil

View full text Add to dashboard Cite

Background Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystemic involvement. Gastrointestinal (GI) manifestations are frequent but functional gastrointestinal disorders (FGIDs) have scarcely been studied in SLE. To determine the prevalence of FGIDs and their potential risk factors in SLE female patients vs controls. Methods Systemic lupus erythematosus patients meeting the American College of Rheumatology (ACR) criteria and controls completed the Rome III questionnaire for FGIDs and a structured interview to assess sociodemographic, clinical, and treatment variables after excluding organic GI diseases. Logistic regression was used to determine risk factors (ie, alcohol drinking, medications) for FGIDs. Key Results Responders included 113 SLE patients and 122 age‐matched controls. The presence of at least one FGIDs was higher in SLE (73.4%) vs controls (54.1%), P = .003. The most frequent FGIDs in SLE patients were nausea and vomiting disorders (NVD), belching disorders, globus, anorectal pain, functional heartburn (FH), and functional bloating (FB). After adjustment for confounding variables, SLE was associated with NVD (OR: 7.1, 95% CI: 2.7‐19.1) globus (3.5, 1.3‐9.3), anorectal pain (3.4, 1.4‐8.4), and FH (2.5, 1.5‐4.4). The simultaneous presence of >1 FGID was more common in SLE patients than controls (69.8% vs 31.8%). Glucocorticoids (5.2, 1.3‐19.9) and non‐steroidal anti‐inflammatory drugs (NSAIDs; 3.0, 1.1‐8.0) were associated with any FGID in SLE patients while alcohol drinking with gallbladder/sphincter of Oddi disorders 7.4 (1.1‐47.3). Conclusions and Inferences Functional gastrointestinal disorders are more frequent in SLE patients compared with controls. Medication that may alter gastrointestinal homeostasis, such as glucocorticoids and NSAIDs, are potential risk factors for FGIDs in SLE.

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 73%

Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study

Garcı́a-Carrasco

Mendoza‐Pinto

Munguía‐Realpozo

et al. 2019

Neurogastroenterology Motil

View full text Add to dashboard Cite

show abstract

“…Corticosteroids have a central role in the treatment of SLE . According to one study, up to 80% of SLE patients are treated with corticosteroids during the course of their disease, most of them for long periods .…”

Section: Discussionmentioning

confidence: 99%

“…37 Corticosteroids have a central role in the treatment of SLE. 38 According to one study, up to 80% of SLE patients are treated with corticosteroids during the course of their disease, most of them for long periods. 39 Earlier reports ascribed dementia to steroid treatment, and subsequent cognitive improvement was observed following their cessation.…”

Section: Discussionmentioning

confidence: 99%

High proportions of dementia among SLE patients: A big data analysis

Gendelman

Tiosano

Shoenfeld

et al. 2017

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…The patient's prognosis with the SLE or SLE is known to be considerably improved with 20 years of survival now roughly about 80% partly owing to the treatments which are effective [10]. SLE is thought to be a "multisystem autoimmune disease" that tends to impact different organs as well as tissue in an individual's body ultimately causing dysfunction and damage.…”

Section: Discussionmentioning

confidence: 99%

Diagnosis and Management of Systemic Lupus Erythematosus: A Case Report

Huneif

2017

J Med Cases

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease with a broad clinical presentation, which is principally difficult to diagnose across the emergency departments (EDs). The immune system of the body in this disease mistakenly damages or attacks healthy tissues. Majority of the patients suffering from SLE tend to develop "secondary heart disease" once in a while throughout the course of their primary illness. This study aimed to report a case of a previously healthy 9-year-old Saudi female who presented with rheumatic fever and congestive heart failure accompanied by productive cough, chest, abdomen, and back pain. A 9-year-old Saudi female was presented to the emergency department with a history of progressive rheumatic fever, iron deficiency anemia, and pain in chest with productive cough. Examination revealed that patient felt extremely ill, pale, afebrile, with a loss of appetite, tachycardic, high grade fever (39 °C), tachypneic, and a peripheral oxygen saturation of 95% on 40% supplemented oxygen" with low blood pressure 105/70 was noted. The patient was assumed to be diagnosed with probable SLE. We started our patient on methylprednisolone, omeprazole, and prednisolon and noticed sustained improvements. Multisystemic and acute life-threatening conditions should arise the suspicion of autoimmune diseases, predominantly SLE in the ED. SLE treatment shall be planned separately with consideration to utilize the "best-suited therapy" for targeting the organ systems affected. Lack of an explicit biological marker, disease heterogeneity, as well as absence of a specific outcome measurement for improvement makes this procedure harder.

show abstract

Contemporary treatment of systemic lupus erythematosus: an update for clinicians

Cited by 63 publications

References 85 publications

Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study

Functional gastrointestinal disorders in women with systemic lupus erythematosus: A case‐control study

High proportions of dementia among SLE patients: A big data analysis

Diagnosis and Management of Systemic Lupus Erythematosus: A Case Report

Contact Info

Product

Resources

About